NHS Integration Skin Analytics has an established NHS footprint since 2020 with DERM deployed across 25 primary and secondary care organisations, presenting a ready-made pathway for expansion within public health systems and potential partnerships with national dermatology programs.

Regulatory Validation DERM is the only Class III CE marked AI Medical Device for skin cancer and is recommended by NICE, signaling a high trust level and a strong differentiator when engaging hospitals, clinics, and insurers seeking validated AI solutions.

Operational Impact To date, pathways have helped avoid up to 95% of face-to-face secondary care appointments and identified over 15,500 cancers across 170,000 NHS patients, offering a compelling value proposition around capacity relief and early cancer detection.

Global Partnerships Recent and ongoing collaborations with Healthdirect Australia, Nordic partners via Human Bytes, and European deployments through Affidea indicate a scalable international expansion thesis and opportunities with private insurers and regional health authorities.

Funding Momentum With a Series B of £15M and total funding of $31M, Skin Analytics demonstrates strong investor support and a growth runway that can fuel regional sales teams, channel partnerships, and longer sales cycles with large health systems and insurers.